Jonathan Stretch, DPhil

Affiliations: 
1989-1992 University of Oxford, Oxford, United Kingdom 
Website:
https://www.melanoma.org.au/about-the-institute/our-team/stretch/
Google:
"Jonathan Stretch"
BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Diefenbach RJ, Lee JH, Stewart A, et al. (2022) Anchored Multiplex PCR Custom Melanoma Next Generation Sequencing Panel for Analysis of Circulating Tumor DNA. Frontiers in Oncology. 12: 820510
El Sharouni MA, Scolyer RA, van Gils CH, et al. (2022) Time interval between diagnostic excision-biopsy of a primary melanoma and sentinel node biopsy: effects on the sentinel node positivity rate and survival outcomes. European Journal of Cancer (Oxford, England : 1990)
El Sharouni MA, Scolyer RA, van Gils CH, et al. (2022) Effect of the time interval between melanoma diagnosis and sentinel node biopsy on the size of metastatic tumour deposits in node-positive patients. European Journal of Cancer (Oxford, England : 1990)
Scolyer RA, Atkinson V, Gyorki DE, et al. (2021) BRAF mutation testing for patients diagnosed with stage III or stage IV melanoma: practical guidance for the Australian setting. Pathology
Aivazian K, Ahmed T, El Sharouni MA, et al. (2021) Histological regression in melanoma: impact on sentinel lymph node status and survival. Modern Pathology : An Official Journal of the United States and Canadian Academy of Pathology, Inc
Harris CG, Lo S, Ahmed T, et al. (2020) Primary dermal melanoma: clinical behaviour, prognosis and treatment. European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
Diefenbach RJ, Lee JH, Strbenac D, et al. (2019) Analysis of the Whole-Exome Sequencing of Tumor and Circulating Tumor DNA in Metastatic Melanoma. Cancers. 11
Nijhuis AAG, Spillane AJ, Stretch JR, et al. (2019) Current management of patients with melanoma who are found to be sentinel node-positive. Anz Journal of Surgery
Long GV, Saw RPM, Lo S, et al. (2019) Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB-C, BRAF mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trial. The Lancet. Oncology
Colebatch AJ, Ferguson P, Newell F, et al. (2019) Molecular genomic profiling of melanocytic nevi. The Journal of Investigative Dermatology
See more...